Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4
Our study suggests that serum NfL, but not GFAP, is a potential diagnostic biomarker in degenerative UMN diseases and may help to differentiate PLS from pure and complicated forms of HSP. Our results indicate that axonal degeneration-the source of NfL release-is predominant over astrocytic pathology-the source of GFAP release-in PLS, AMN, and SPG4.
Authors
- Holger Hengel (ORCID: https://orcid.org/0000-0002-9773-2667)
- Jens Kühle (ORCID: https://orcid.org/0000-0002-6963-8892)
- Tim W. Rattay (ORCID: https://orcid.org/0000-0002-5456-7761)
- Christoph Keßler (ORCID: https://orcid.org/0000-0001-6211-903X)
- Carlo Wilke (ORCID: https://orcid.org/0000-0002-7250-8597)
- Ludger J. Schöls (ORCID: https://orcid.org/0000-0001-7774-5025)
- Aleksandra Maleska Maceski (ORCID: https://orcid.org/0000-0002-1916-5927)
- Rebecca Schüle (ORCID: https://orcid.org/0000-0002-7781-2766)
Institutions
- Heidelberg University (DE)
- German Center for Neurodegenerative Diseases (DE)
- University Hospital Heidelberg (DE)
- University Hospital of Basel (CH)
- Department of Biomedicine Basel (CH)
- Hertie Institute for Clinical Brain Research (DE)
- Institute of Neuroimmunology of the Slovak Academy of Sciences (SK)
- Neurological Surgery (US)
- Rehaklinik Zihlschlacht (CH)
Publication Details
- Journal
- Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Published
- 2025-09-17
- DOI
- https://doi.org/10.1080/21678421.2025.2557936
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00